171 related articles for article (PubMed ID: 23299389)
1. Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.
Kim KW; Lee JM; Jeon YS; Lee IJ; Choi Y; Park J; Kiefer B; Kim C; Han JK; Choi BI
Invest New Drugs; 2013 Oct; 31(5):1097-106. PubMed ID: 23299389
[TBL] [Abstract][Full Text] [Related]
2. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
Moon CH; Lee SJ; Lee HY; Dung le TK; Cho WJ; Cha H; Park JW; Min YJ
Invest New Drugs; 2014 Jun; 32(3):400-11. PubMed ID: 24202729
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Contrast-Enhanced MRI Using a Macromolecular MR Contrast Agent (P792): Evaluation of Antivascular Drug Effect in a Rabbit VX2 Liver Tumor Model.
Park HS; Han JK; Lee JM; Kim YI; Woo S; Yoon JH; Choi JY; Choi BI
Korean J Radiol; 2015; 16(5):1029-37. PubMed ID: 26357497
[TBL] [Abstract][Full Text] [Related]
4. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Ji YT; Liu YN; Liu ZP
Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
[TBL] [Abstract][Full Text] [Related]
5. Monitoring Vascular Disrupting Therapy in a Rabbit Liver Tumor Model: Relationship between Tumor Perfusion Parameters at IVIM Diffusion-weighted MR Imaging and Those at Dynamic Contrast-enhanced MR Imaging.
Joo I; Lee JM; Grimm R; Han JK; Choi BI
Radiology; 2016 Jan; 278(1):104-13. PubMed ID: 26200601
[TBL] [Abstract][Full Text] [Related]
6. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors.
Joo I; Lee JM; Han JK; Choi BI
Radiology; 2014 Aug; 272(2):417-26. PubMed ID: 24697148
[TBL] [Abstract][Full Text] [Related]
7. Monitoring tumor response to the vascular disrupting agent CKD-516 in a rabbit VX2 intramuscular tumor model using PET/MRI: Simultaneous evaluation of vascular and metabolic parameters.
Ahn SY; Goo JM; Lee KH; Ha S; Paeng JC
PLoS One; 2018; 13(2):e0192706. PubMed ID: 29438381
[TBL] [Abstract][Full Text] [Related]
8. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG
Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746
[TBL] [Abstract][Full Text] [Related]
9. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4.
Fruytier AC; Magat J; Neveu MA; Karroum O; Bouzin C; Feron O; Jordan B; Cron GO; Gallez B
NMR Biomed; 2014 Nov; 27(11):1403-12. PubMed ID: 25323069
[TBL] [Abstract][Full Text] [Related]
11. Science to practice: can intravoxel incoherent motion diffusion-weighted MR imaging be used to assess tumor response to antivascular drugs?
Koh DM
Radiology; 2014 Aug; 272(2):307-8. PubMed ID: 25058129
[TBL] [Abstract][Full Text] [Related]
12. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
[TBL] [Abstract][Full Text] [Related]
13. Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo.
Kretzschmann VK; Gellrich D; Ullrich A; Zahler S; Vollmar AM; Kazmaier U; Fürst R
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):294-303. PubMed ID: 24285578
[TBL] [Abstract][Full Text] [Related]
14. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.
Lee J; Kim SJ; Choi H; Kim YH; Lim IT; Yang HM; Lee CS; Kang HR; Ahn SK; Moon SK; Kim DH; Lee S; Choi NS; Lee KJ
J Med Chem; 2010 Sep; 53(17):6337-54. PubMed ID: 20690624
[TBL] [Abstract][Full Text] [Related]
15. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
Rice L; Pampo C; Lepler S; Rojiani AM; Siemann DW
Microvasc Res; 2011 Jan; 81(1):44-51. PubMed ID: 20974154
[TBL] [Abstract][Full Text] [Related]
16. Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response.
Sampath D; Oeh J; Wyatt SK; Cao TC; Koeppen H; Eastham-Anderson J; Robillard L; Ho CC; Ross J; Zhuang G; Reslan HB; Vitorino P; Barck KH; Ungersma SE; Vernes JM; Caunt M; Van Bruggen N; Ye W; Vijapurkar U; Meng YJ; Ferrara N; Friedman LS; Carano RA
Neoplasia; 2013 Jul; 15(7):694-711. PubMed ID: 23814482
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.
Kim MY; Shin JY; Kim JO; Son KH; Kim YS; Jung CK; Kang JH
BMC Cancer; 2020 Nov; 20(1):1057. PubMed ID: 33143663
[TBL] [Abstract][Full Text] [Related]
18. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S
J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355
[TBL] [Abstract][Full Text] [Related]
19. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
McPhail LD; McIntyre DJ; Ludwig C; Kestell P; Griffiths JR; Kelland LR; Robinson SP
Neoplasia; 2006 Mar; 8(3):199-206. PubMed ID: 16611413
[TBL] [Abstract][Full Text] [Related]
20. Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.
Liu L; O'Kelly D; Schuetze R; Carlson G; Zhou H; Trawick ML; Pinney KG; Mason RP
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
